These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33447857)

  • 1. Retinal venous pressure is decreased after anti-VEGF therapy in patients with retinal vein occlusion-related macular edema.
    Kida T; Flammer J; Konieczka K; Ikeda T
    Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):1853-1858. PubMed ID: 33447857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
    Hu Q; Li H; Xu W; Du Y; Ma C; He J
    Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
    Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
    JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.
    Blanc J; Deschasse C; Kodjikian L; Dot C; Bron AM; Creuzot-Garcher C
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1441-1448. PubMed ID: 29855706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
    Song S; Yu X; Zhang P; Gu X; Dai H
    BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
    JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Follow-Up Changes of Central Choroidal Thickness Thinning after Repeated Anti-VEGF Therapy Injections in Patients with Central Retinal Vein Occlusion-Related Macular Edema with Systemic Hypertension.
    Kida T; Osuka S; Fukumoto M; Sato T; Harino S; Oku H; Ikeda T
    Ophthalmologica; 2020; 243(2):102-109. PubMed ID: 31851998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study.
    Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
    BMC Ophthalmol; 2017 Jun; 17(1):90. PubMed ID: 28610573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
    Aref AA; Scott IU; VanVeldhuisen PC; King J; Ip MS; Blodi BA; Oden NL;
    JAMA Ophthalmol; 2021 Dec; 139(12):1285-1291. PubMed ID: 34709363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The correlation between cytokine levels in the aqueous humor and the prognostic value of anti-vascular endothelial growth factor therapy for treating macular edema resulting from retinal vein occlusion.
    Yong H; Qi H; Yan H; Wu Q; Zuo L
    Graefes Arch Clin Exp Ophthalmol; 2021 Nov; 259(11):3243-3250. PubMed ID: 34059950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
    Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
    Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
    Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
    Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: 6-MONTH RESULT.
    Terashima H; Hasebe H; Okamoto F; Matsuoka N; Sato Y; Fukuchi T
    Retina; 2019 Jul; 39(7):1377-1384. PubMed ID: 29689025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
    Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
    Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
    Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
    Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions.
    Dascalu AM; Popa-Cherecheanu A; Popa-Cherecheanu M; Nica A; Serban D
    Rom J Ophthalmol; 2016; 60(2):90-95. PubMed ID: 29450329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion.
    Loukianou E; Brouzas D; Chatzistefanou K; Koutsandrea C
    Int Ophthalmol; 2016 Feb; 36(1):21-36. PubMed ID: 25820576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.